289 related articles for article (PubMed ID: 28228084)
21. Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.
Uusi-Kerttula H; Hulin-Curtis S; Davies J; Parker AL
Viruses; 2015 Nov; 7(11):6009-42. PubMed ID: 26610547
[TBL] [Abstract][Full Text] [Related]
22. Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses.
Brugada-Vilà P; Cascante A; Lázaro MÁ; Castells-Sala C; Fornaguera C; Rovira-Rigau M; Albertazzi L; Borros S; Fillat C
Theranostics; 2020; 10(6):2744-2758. PubMed ID: 32194832
[TBL] [Abstract][Full Text] [Related]
23. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.
Nishimoto T; Yoshida K; Miura Y; Kobayashi A; Hara H; Ohnami S; Kurisu K; Yoshida T; Aoki K
Gene Ther; 2009 May; 16(5):669-80. PubMed ID: 19225547
[TBL] [Abstract][Full Text] [Related]
25. Chapter four--Design of improved oncolytic adenoviruses.
Alemany R
Adv Cancer Res; 2012; 115():93-114. PubMed ID: 23021243
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models.
Miao T; Symonds A; Hickman OJ; Wu D; Wang P; Lemoine N; Wang Y; Linardopoulos S; Halldén G
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279262
[TBL] [Abstract][Full Text] [Related]
27. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
[TBL] [Abstract][Full Text] [Related]
28. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer.
Lucas T; Benihoud K; Vigant F; Schmidt CQ; Wortmann A; Bachem MG; Simmet T; Kochanek S
PLoS One; 2015; 10(2):e0117254. PubMed ID: 25692292
[TBL] [Abstract][Full Text] [Related]
29. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
[TBL] [Abstract][Full Text] [Related]
30. Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer.
Kangasniemi L; Parviainen S; Pisto T; Koskinen M; Jokinen M; Kiviluoto T; Cerullo V; Jalonen H; Koski A; Kangasniemi A; Kanerva A; Pesonen S; Hemminki A
Int J Cancer; 2012 Jul; 131(1):253-63. PubMed ID: 21834073
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Human Pancreatic Cancers Following Local and Systemic Administration of Oncolytic Adenovirus Serotype 35.
Ono R; Takayama K; Onishi R; Tokuoka S; Sakurai F; Mizuguchi H
Anticancer Res; 2023 Feb; 43(2):537-546. PubMed ID: 36697099
[TBL] [Abstract][Full Text] [Related]
32. Strategies for enhancing intratumoral spread of oncolytic adenoviruses.
Goradel NH; Negahdari B; Ghorghanlu S; Jahangiri S; Arashkia A
Pharmacol Ther; 2020 Sep; 213():107586. PubMed ID: 32479843
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic virotherapy for pancreatic cancer.
Wennier S; Li S; McFadden G
Expert Rev Mol Med; 2011 May; 13():e18. PubMed ID: 21676289
[TBL] [Abstract][Full Text] [Related]
34. Evolution of oncolytic adenovirus for cancer treatment.
Choi JW; Lee JS; Kim SW; Yun CO
Adv Drug Deliv Rev; 2012 Jun; 64(8):720-9. PubMed ID: 22212901
[TBL] [Abstract][Full Text] [Related]
35. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
[TBL] [Abstract][Full Text] [Related]
36. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
37. Current issues and future directions of oncolytic adenoviruses.
Yamamoto M; Curiel DT
Mol Ther; 2010 Feb; 18(2):243-50. PubMed ID: 19935777
[TBL] [Abstract][Full Text] [Related]
38. Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force.
Tresilwised N; Pithayanukul P; Mykhaylyk O; Holm PS; Holzmüller R; Anton M; Thalhammer S; Adigüzel D; Döblinger M; Plank C
Mol Pharm; 2010 Aug; 7(4):1069-89. PubMed ID: 20550160
[TBL] [Abstract][Full Text] [Related]
39. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin.
Yoon AR; Kim JH; Lee YS; Kim H; Yoo JY; Sohn JH; Park BW; Yun CO
Hum Gene Ther; 2006 Apr; 17(4):379-90. PubMed ID: 16610926
[TBL] [Abstract][Full Text] [Related]
40. A novel oncolytic adenovirus based on simian adenovirus serotype 24.
Cheng T; Song Y; Zhang Y; Zhang C; Yin J; Chi Y; Zhou D
Oncotarget; 2017 Apr; 8(16):26871-26885. PubMed ID: 28460470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]